Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region

Antiviral Research

Volumn 110, Issue 1, 2014, Pages 52-59

  Irving, William L ^a   Rupp, Daniel ^b   McClure, C Patrick ^a   Than, Lwin Mar ^a   Titman, Andrew ^a   Ball, Jonathan K ^a   Steinmann, Eike ^c   Bartenschlager, Ralf ^b   Pietschmann, Thomas ^c   Brown, Richard J P ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Chronic infection; HCV NS3 protease; Pyrosequencing; RAV persistence

Indexed keywords

AMINO ACID; BOCEPREVIR; FALDEPREVIR; PEGINTERFERON ALPHA; PROTEINASE; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; PROLINE; VIRUS PROTEIN;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PURIFYING SELECTION; PYROSEQUENCING; RETROSPECTIVE STUDY; TREATMENT FAILURE; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; GENETIC VARIABILITY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH THROUGHPUT SEQUENCING; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; PROCEDURES; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, RNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84905851930     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.07.009     Document Type: Article

References (28)

1. R. Bartenschlager, V. Lohmann, and F. Penin The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection Nat. Rev. Microbiol. 11 2013 482 496
2. K.L. Berger, L. Lagace, I. Triki, M. Cartier, M. Marquis, C. Lawetz, R. Bethell, J. Scherer, and G. Kukolj Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study Antimicrob. Agents Chemother. 57 2013 4928 4936
3. K. Esser-Nobis, I. Romero-Brey, T.M. Ganten, J. Gouttenoire, C. Harak, R. Klein, P. Schemmer, M. Binder, P. Schnitzler, D. Moradpour, R. Bartenschlager, S.J. Polyak, W. Stremmel, F. Penin, C. Eisenbach, and V. Lohmann Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B Hepatology 57 2013 953 963
4. P. Friebe, J. Boudet, J.P. Simorre, and R. Bartenschlager Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication J. Virol. 79 2005 380 392 (Pubitemid 39648391)
5. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, M. Sulkowski, J.G. McHutchison, and D.B. Goldstein Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
6. L. Gravitz Introduction: a smouldering public-health crisis Nature 474 2011 S2 S4
7. P. Halfon, and S. Locarnini Hepatitis C virus resistance to protease inhibitors J. Hepatol. 55 2011 192 206
8. J.H. Hoofnagle Course and outcome of hepatitis C Hepatology 36 2002 S21 S29
9. I. Imhof, and P. Simmonds Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6 J. Virol. 84 2010 4597 4610
10. G. Koutsoudakis, A. Kaul, E. Steinmann, S. Kallis, V. Lohmann, T. Pietschmann, and R. Bartenschlager Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses J. Virol. 80 2006 5308 5320
11. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, S.K. Young, B. Lee, D. Heckerman, J. Carlson, L.L. Reyor, M. Kleyman, C.M. McMahon, and C. Birch et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
12. L. Lagace, P.W. White, C. Bousquet, N. Dansereau, F. Do, M. Llinas-Brunet, M. Marquis, M.J. Massariol, R. Maurice, C. Spickler, D. Thibeault, I. Triki, S. Zhao, and G. Kukolj In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335 Antimicrob. Agents Chemother. 56 2012 569 572
13. O. Lenz, T. Verbinnen, T.I. Lin, L. Vijgen, M.D. Cummings, J. Lindberg, J.M. Berke, P. Dehertogh, E. Fransen, A. Scholliers, K. Vermeiren, T. Ivens, P. Raboisson, M. Edlund, S. Storm, L. Vrang, H. de Kock, G.C. Fanning, and K.A. Simmen In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob. Agents Chemother. 54 2010 1878 1887
14. M. Llinas-Brunet, M.D. Bailey, N. Goudreau, P.K. Bhardwaj, J. Bordeleau, M. Bos, Y. Bousquet, M.G. Cordingley, J. Duan, P. Forgione, M. Garneau, E. Ghiro, V. Gorys, S. Goulet, T. Halmos, S.H. Kawai, J. Naud, M.A. Poupart, and P.W. White Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335) J. Med. Chem. 53 2010 6466 6476
15. V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113 (Pubitemid 29307577)
16. X. Qi, A. Bae, S. Liu, H. Yang, S.C. Sun, J. Harris, W. Delaney, M. Miller, and H. Mo Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates Antivir. Res. 81 2009 166 173
17. A.D. Radford, D. Chapman, L. Dixon, J. Chantrey, A.C. Darby, and N. Hall Application of next-generation sequencing technologies in virology J. Gen. Virol. 93 2012 1853 1868
18. Report 2013. FDA ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING OCTOBER 24, 2013 BACKGROUND PACKAGE FOR NDA 205123 SIMEPREVIR (TMC435).
19. K.A. Salam, and N. Akimitsu Hepatitis C virus NS3 inhibitors: current and future perspectives Biomed. Res. Int. 2013 2013 467869
20. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
21. T. Sheahan, N. Imanaka, S. Marukian, M. Dorner, P. Liu, A. Ploss, and C.M. Rice Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness Cell Host Microbe 15 2014 190 202
22. Y.K. Shimizu, M. Hijikata, M. Oshima, K. Shimizu, and H. Yoshikura Detection of a 5' end subgenome of hepatitis C virus terminating at nucleotide 384 in patients' plasma and liver tissues J. Viral Hepat. 13 2006 746 755 (Pubitemid 44583500)
23. M.S. Sulkowski, T. Asselah, J. Lalezari, P. Ferenci, H. Fainboim, B. Leggett, F. Bessone, S. Mauss, J. Heo, Y. Datsenko, J.O. Stern, G. Kukolj, J. Scherer, G. Nehmiz, G.G. Steinmann, and W.O. Bocher Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial Hepatology 57 2013 2143 2154
24. M.S. Sulkowski, M. Bourliere, J.P. Bronowicki, T. Asselah, J.M. Pawlotsky, S.D. Shafran, S. Pol, S. Mauss, D. Larrey, Y. Datsenko, J.O. Stern, G. Kukolj, J. Scherer, G. Nehmiz, G.G. Steinmann, and W.O. Bocher Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial Hepatology 57 2013 2155 2163
25. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Muller, M. Bahlo, G.J. Stewart, D.R. Booth, and J. George IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat. Genet. 41 2009 1100 1104
26. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, S. Hige, Y. Ito, E. Mita, E. Tanaka, S. Mochida, Y. Murawaki, M. Honda, A. Sakai, Y. Hiasa, S. Nishiguchi, A. Koike, I. Sakaida, M. Imamura, K. Ito, K. Yano, N. Masaki, F. Sugauchi, N. Izumi, K. Tokunaga, and M. Mizokami Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat. Genet. 41 2009 1105 1109
27. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, C. O'Huigin, J. Kidd, K. Kidd, S.I. Khakoo, G. Alexander, J.J. Goedert, G.D. Kirk, S.M. Donfield, H.R. Rosen, L.H. Tobler, M.P. Busch, J.G. McHutchison, D.B. Goldstein, and M. Carrington Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
28. C. Welsch, A. Jesudian, S. Zeuzem, and I. Jacobson New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives Gut 61 Suppl 1 2012 i36 i46